SCHEMBL6742412

SCHEMBL6742412

CCCN(CCC)C(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ BLM P54132 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ DPP4 P27487 3/20 0.40
▸ DPP9 Q86TI2 2/20 0.40
▸ DPP8 Q6V1X1 1/20 0.40
▸ CA12 O43570 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ DDAH1 O94760 1/20 0.33
▸ NOS1 P29475 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10891103 1.00 KMT2A (0.48) KMT2AALOX15BLMPMP22DPP4
SCHEMBL21312920 0.93 ALOX15 (0.46) KMT2AALOX15BLMPMP22DPP4
SCHEMBL28494490 0.86 KMT2A (0.43) KMT2AALOX15BLMPMP22CA12
SCHEMBL6464158 0.85 DPP4 (0.51) BLMDPP4DPP9DPP8ALDH1A1
SCHEMBL3353776 0.85 DPP4 (0.51) BLMDPP4DPP9DPP8ALDH1A1
SCHEMBL16240125 0.85 DPP4 (0.51) BLMDPP4DPP9DPP8ALDH1A1
SCHEMBL5791770 0.85 ALOX15 (0.52) KMT2AALOX15BLMPMP22DPP4
SCHEMBL24458242 0.81 DPP7 (0.46) DPP4DPP9DPP8CA12CA2
SCHEMBL27625475 0.81 CA12 (0.39) DPP4CA12CA2CA9ALDH1A1
Trifluoroacetic Acid SCHEMBL3350406 0.77 DPP4 (0.44) DPP4DPP9DPP8ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229848-A1 Glutaminyl based DP IV-inhibitors PROSIDION LIMITED (GB) 2004-11-18 — — US disclosed
EP-0078152-B1 SALTS OF SULFODEHYDROABIETIC ACID AND TREATMENT OF GASTRO-INTESTINAL DISEASES Tanabe Seiyaku Co., Ltd. (JP) 1986-05-07 — — EP disclosed
US-4529602-A Sulfodehydroabietic acid compound TANABE SEIYAKU CO., LTD. (JP) 1985-07-16 — — US disclosed
EP-0078152-A1 Salts of sulfodehydroabietic acid and treatment of gastro-intestinal diseases Tanabe Seiyaku Co., Ltd. (JP) 1983-05-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229848-A1 Glutaminyl based DP IV-inhibitors DPP4, DPP3, DNPEP KMT2A 2304/4885ALOX15 4131/4885BLM 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback